louis l. nguyen, md, mba, mph division of vascular & endovascular surgery
DESCRIPTION
Economic Considerations in Defining The SVS Research Priorities. Louis L. Nguyen, MD, MBA, MPH Division of Vascular & Endovascular Surgery and the Center for Surgery & Public Health Brigham & Women ’ s Hospital Harvard Medical School. Rising Health Care costs. Hidden Costs of Health Care. - PowerPoint PPT PresentationTRANSCRIPT
Louis L. Nguyen, MD, MBA, MPH
Division of Vascular & Endovascular Surgery and the Center for Surgery & Public Health
Brigham & Women’s HospitalHarvard Medical School
Economic Considerations in Defining
The SVS Research Priorities
Rising Health Care costs
Hidden Costs of Health Care
Time off to care for family members $363B (Deloitte Center for Health Solutions)
Companies reduce workforce to decrease healthcare costs
Increased deductibles and co-pays Puts families at greater financial risk
Potential Changes Insurance mandate
Reduces adverse selection by forcing everyone to carry insurance
Universal health care Single payer controls cost by dictating price
Greater income equality among medical specialties Focus on prevention and cost containment
Bundled payments Shifts risk on to providers and hospitals
Likely Consequences Greater awareness of costs and outcomes
Payers and patients will want to know
“Cost” – the Other Four-Letter Word
Medical professionals avoid dealing with costs “I do what’s best for my patient, regardless of
costs”
Patients believe health care is a right “I want everything done”
Using costs to decide treatment is heartless “Death panels”
Why Use Economics Considerations?
Economics is the field of study that analyzes the production, distribution, and consumption of goods and services
Economics assumes that resources are constrained
Economics is objective and quantitative
Health care economics is about asymmetric information
How Do We Value Health Care?
How Do We Prioritize Our Research?
Cost Effectiveness Framework
Determine analysis perspective Calculate costs Calculate outcomes (effectiveness) Standardize the unit of measure (QALY)
Compare cost-effectiveness and make adjustments
The Societal Perspective Who benefits? Who pays for the costs?
Patients Providers Insurers Society
Costs vs. Charges Cost is the value of the inputs used to
produce a product/service
Charge is the price demanded by the seller
Opportunity cost is the value of the next best alternative that was forgone
Outcomes Cost-Effectiveness
Quality-adjusted life-years (QALY) Utility Cost-Benefit
Monetary measures
Cost-Effectiveness SpaceEff
ecti
vene
ss
Costs
Inferior
Superior
Trade-off
Trade-off
Using Cost Effectiveness Analyses
Incremental Cost Effectiveness Ratio (ICER) Ratio of change in cost to change in
effectiveness between one therapy and the next best therapy
Cost effectiveness league tables List of increasing cost-effectiveness non-
exclusive therapies Therapies are chosen until budget is met or
ICER limit is reached
Special Considerations
High Impact Small improvements in large numbers of
people Early improvements can prevent disease
Prevention Primary Prevention
Strategies to avoid the development of disease Secondary Prevention
Strategies to diagnose or treat disease before development of morbidity
Tertiary Prevention Strategies to reduce the negative impact of established
disease Quaternary Prevention
Strategies to avoid consequences of unnecessary treatments
Real World Outcomes
59% of patients had maximum diameter less than 5.5cm42%/69% of patients had anatomy meeting conservative/liberal criteria41% 5-year sac enlargement rate
Treatment Choices Angioplasty/stenting: less costly and but
effective Surgical bypass: more costly but more
effective
Sequential treatment Angioplasty/stenting first Bypass if angioplasty/stenting fails
Depends on failure rates and impact of stenting on bypass
Mortality Mortality hides poor quality care Mortality ends health care spending
LOS measurements in high mortality procedures can be underestimate resources
Health Services Research
Non-Randomized TrialsAdvantages Less cost Faster enrollment Reflects real-world patients and practice
Disadvantages Treatment bias Complex mathematics to control for
confounding
Cost Analysis of Face Transplantation vs.
Conventional Reconstruction BWH pioneers of full
face transplantation (4 to date)
Raw results Cost modeling
Technology and innovation has costs
Assess costs early in the process
Provider Induced Demand
Heath care is an agency problem with asymmetric information
The principal (patient) appoints an agent (doctor) to advise them about consumption of health care
The agent is also the supplier of health care
The agent influences demand and supply!
Current PID evidence is anecdotal or temporally controlled
Comparative Effectiveness and Provider Induced Demand Collaboration (EPIC):
A Clinical and Economic Analysis of Variation In Health Care
Collaboration with the Uniformed Services University
Analysis of the TRICARE Heath System (9.3M pts)
Patients receive care in two systems Military Hospitals with salaries physicians Private Hospitals with fee-for-service physicians
Do physicians induce demand for health care? What are the hidden costs/benefits of treatment?
Summary Health care reform is already here Economic analysis is an objective tool to
quantify tradeoffs between costs and benefits
All large studies should consider costs HSR to look at the way we practice
Economics can only show tradeoffs – society must make decisions about which tradeoffs we accept
“The medical profession is only one example, though in many respects an extreme one. All professions share some of the same properties. The economic importance of personal and especially family relationships, though declining, is by no means trivial in the most advanced economies; it is based on non-market relations that create guarantees of behavior which would otherwise be afflicted with excessive uncertainty.”
--Kenneth J. Arrow, 1963
Contact information
Louis L. Nguyen, MD, MBA, MPHVascular & Endovascular Surgery
Brigham & Women’s Hospital75 Francis StreetBoston, MA 02115
(857) [email protected]